CAPItello-281 (NCT04493853) is an ongoing Phase 3, randomized, double-blind trial evaluating the efficacy and safety of capivasertib, a selective oral pan-AKT inhibitor, in combination with abiraterone and ADT in patients with de novo mHSPC and PTEN loss, a deficiency common in prostate cancer that leads to PI3K/AKT pathway hyperactivation and resistance to AR inhibitors. This evidence concerns the gene PTEN and prostate carcinoma.